156 related articles for article (PubMed ID: 36644658)
1. Epidemiology and Mortality Analysis Related to Carbapenem-Resistant Enterobacterales in Patients After Admission to Intensive Care Units: An Observational Study.
Yoo EH; Hong HL; Kim EJ
Infect Drug Resist; 2023; 16():189-200. PubMed ID: 36644658
[TBL] [Abstract][Full Text] [Related]
2. Multicenter study on the prevalence of colonization due to carbapenem-resistant
Fasciana T; Antonelli A; Bianco G; Lombardo D; Codda G; Roscetto E; Perez M; Lipari D; Arrigo I; Galia E; Tricoli MR; Calvo M; Niccolai C; Morecchiato F; Errico G; Stefani S; Cavallo R; Marchese A; Catania MR; Ambretti S; Rossolini GM; Pantosti A; Palamara AT; Sabbatucci M; Serra N; Giammanco A
Front Public Health; 2023; 11():1270924. PubMed ID: 38186699
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and risk factors of carbapenem-resistant
Guo B; Guo Z; Zhang H; Shi C; Qin B; Wang S; Chang Y; Chen J; Chen P; Guo L; Guo W; Han H; Han L; Hu Y; Jin X; Li Y; Liu H; Lou P; Lu Y; Ma P; Shan Y; Sun Y; Zhang W; Zheng X; Shao H
Front Microbiol; 2022; 13():894341. PubMed ID: 36187994
[TBL] [Abstract][Full Text] [Related]
4. Imipenem-Relebactam Susceptibility in
Hernández-García M; García-Castillo M; Bou G; Cercenado E; Delgado-Valverde M; Oliver A; Pitart C; Rodríguez-Lozano J; Tormo N; Melo-Cristino J; Pinto MF; Gonçalves E; Alves V; Vieira AR; Ramalheira E; Sancho L; Diogo J; Ferreira R; Cruz H; Chaves C; Duarte J; Pássaro L; Díaz-Regañón J; Cantón R
Microbiol Spectr; 2022 Oct; 10(5):e0292722. PubMed ID: 36043877
[TBL] [Abstract][Full Text] [Related]
5. Epidemiology and risk factors of rectal colonization of carbapenemase-producing Enterobacteriaceae among high-risk patients from ICU and HSCT wards in a university hospital.
Yan L; Sun J; Xu X; Huang S
Antimicrob Resist Infect Control; 2020 Sep; 9(1):155. PubMed ID: 32967718
[TBL] [Abstract][Full Text] [Related]
6. An observational study on carbapenem-resistant Enterobacterales (CRE) colonisation and subsequent risk of infection in an adult intensive care unit (ICU) at a tertiary care hospital in India.
Sharma K; Tak V; Nag VL; Bhatia PK; Kothari N
Infect Prev Pract; 2023 Dec; 5(4):100312. PubMed ID: 37868258
[TBL] [Abstract][Full Text] [Related]
7. A Longitudinal Nine-Year Study of the Molecular Epidemiology of Carbapenemase-Producing
Duong TTT; Tsai YM; Wen LL; Chiu HC; Chen PK; Thuy TTD; Kuo PY; Hidrosollo JH; Wang S; Zhang YZ; Lin WH; Wang MC; Kao CY
Front Microbiol; 2022; 13():703113. PubMed ID: 35359715
[TBL] [Abstract][Full Text] [Related]
8. Carbapenemase producing
Carroll A; Carman R; Bannerman T; Pancholi P
Infect Prev Pract; 2024 Jun; 6(2):100366. PubMed ID: 38765915
[TBL] [Abstract][Full Text] [Related]
9. Molecular Epidemiology, Microbial Virulence, and Resistance of Carbapenem-Resistant
Peng C; Feng DH; Zhan Y; Wang Q; Chen DQ; Xu Z; Yang L
Microb Drug Resist; 2022 Jun; 28(6):698-709. PubMed ID: 35639427
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of HiCrome KPC Agar for the Screening of Carbapenem-Resistant Enterobacterales Colonization in the ICU Setting of a Tertiary Care Hospital.
Mahapatra A; Nikitha K; Rath S; Behera B; Gupta K
J Lab Physicians; 2021 Dec; 13(4):358-361. PubMed ID: 34975256
[No Abstract] [Full Text] [Related]
11. Pharmacodynamic evaluation of meropenem, cefepime, or aztreonam combined with a novel β-lactamase inhibitor, nacubactam, against carbapenem-resistant and/or carbapenemase-producing Klebsiella pneumoniae and Escherichia coli using a murine thigh-infection model.
Hagihara M; Kato H; Sugano T; Okade H; Sato N; Shibata Y; Sakanashi D; Asai N; Koizumi Y; Suematsu H; Yamagishi Y; Mikamo H
Int J Antimicrob Agents; 2021 May; 57(5):106330. PubMed ID: 33789129
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and factors associated with carbapenem-resistant Enterobacterales (CRE) infection among hematological malignancies patients with CRE intestinal colonization.
Chen X; Wen X; Jiang Z; Yan Q
Ann Clin Microbiol Antimicrob; 2023 Jan; 22(1):3. PubMed ID: 36627626
[TBL] [Abstract][Full Text] [Related]
13. Monitoring Carbapenem-Resistant Enterobacterales in the Environment to Assess the Spread in the Community.
Urase T; Goto S; Sato M
Antibiotics (Basel); 2022 Jul; 11(7):. PubMed ID: 35884172
[TBL] [Abstract][Full Text] [Related]
14. Risk Factors for Carbapenemase-Producing
Kim YA; Lee SJ; Park YS; Lee YJ; Yeon JH; Seo YH; Lee K
Antibiotics (Basel); 2020 Oct; 9(10):. PubMed ID: 33049912
[TBL] [Abstract][Full Text] [Related]
15. Fecal Carriage and Epidemiology of Carbapenem-Resistant
Liu Q; Liu L; Li Y; Chen X; Yan Q; Liu WE
Infect Drug Resist; 2019; 12():3935-3942. PubMed ID: 31908504
[TBL] [Abstract][Full Text] [Related]
16. ＜Editors' Choice＞ Multicenter survey for carbapenemase-producing Enterobacterales in central Japan.
Hara Y; Iguchi M; Tetsuka N; Morioka H; Hirabayashi A; Suzuki M; Tomita Y; Oka K; Yagi T
Nagoya J Med Sci; 2022 Aug; 84(3):630-639. PubMed ID: 36237878
[TBL] [Abstract][Full Text] [Related]
17. In Vivo Pharmacodynamics of β-Lactams/Nacubactam against Carbapenem-Resistant and/or Carbapenemase-Producing
Hagihara M; Kato H; Sugano T; Okade H; Sato N; Shibata Y; Sakanashi D; Hirai J; Asai N; Suematsu H; Yamagishi Y; Mikamo H
Antibiotics (Basel); 2021 Sep; 10(10):. PubMed ID: 34680760
[TBL] [Abstract][Full Text] [Related]
18. Multicenter Study of Carbapenemase-Producing
Yu H; González Molina MK; Carmona Cartaya Y; Hart Casares M; Aung MS; Kobayashi N; Quiñones Pérez D
Antibiotics (Basel); 2022 Apr; 11(4):. PubMed ID: 35453265
[TBL] [Abstract][Full Text] [Related]
19. Carbapenemase-producing Eenterobacterales from hospital environment and their relation to those from patient specimens.
Kim SH; Kim GR; Kim EY; Jeong J; Kim S; Shin JH
J Infect Public Health; 2022 Feb; 15(2):241-244. PubMed ID: 35065356
[TBL] [Abstract][Full Text] [Related]
20. Molecular characterization of carbapenem-resistant
Yan WJ; Jing N; Wang SM; Xu JH; Yuan YH; Zhang Q; Li AL; Chen LH; Zhang JF; Ma B; Ma Q; Li Y
J Med Microbiol; 2021 Mar; 70(3):. PubMed ID: 33587030
[No Abstract] [Full Text] [Related]
[Next] [New Search]
